Adult-onset Still's disease secondary prevention: Difference between revisions
(Created page with "__NOTOC__ {{Adult-onset Still’s disease}} {{CMG}}; {{AE}} ==Overview== ==Secondary Prevention== ==References== {{reflist|2}} {{WH}} {{WS}}") |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
[[Secondary prevention]] of adult-onset Still's disease (AOSD) is aimed at [[Prevention (medical)|preventing]] [[Relapse|relapses]] of the disease. [[Tocilizumab]] may be used to [[Prevention|prevent]] [[Relapse|relapses]] associated with AOSD. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
[[Secondary prevention]] of adult-onset Still's disease (AOSD) is aimed at [[Prevention|preventing]] [[Relapse|relapses]] of the disease. [[Tocilizumab]] may be used to [[Prevention|prevent]] [[Relapse|relapses]] associated with AOSD.<ref name="pmid25401229">{{cite journal |vauthors=Nishina N, Kaneko Y, Kameda H, Takeuchi T |title=The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study |journal=Mod Rheumatol |volume=25 |issue=3 |pages=401–4 |date=May 2015 |pmid=25401229 |doi=10.3109/14397595.2014.973659 |url=}}</ref> | |||
==References== | ==References== | ||
Latest revision as of 19:08, 24 April 2018
|
Adult-onset Still's disease |
|
Differentiating Adult-onset Still’s Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Template:Adult-onset Still's disease On the Web |
|
American Roentgen Ray Society Images of Template:Adult-onset Still's disease |
|
Template:Adult-onset Still's disease in the news |
|
Risk calculators and risk factors for Template:Adult-onset Still's disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Secondary prevention of adult-onset Still's disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.
Secondary Prevention
Secondary prevention of adult-onset Still's disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.[1]
References
- ↑ Nishina N, Kaneko Y, Kameda H, Takeuchi T (May 2015). "The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study". Mod Rheumatol. 25 (3): 401–4. doi:10.3109/14397595.2014.973659. PMID 25401229.